PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Stürzebecher, P.E.* ; Kralisch, S.* ; Schubert, M.R.* ; Filipova, V.* ; Hoffmann, A.* ; Oliveira, F. ; Sheikh, B. ; Blüher, M. ; Kogel, A.* ; Scholz, M.* ; Kokot, K.E.* ; Erbe, S.* ; Kneuer, J.M.* ; Ebert, T.* ; Fasshauer, M.* ; Miehle, K.* ; Laufs, U.* ; Tönjes, A.* ; Boeckel, J.N.*

Leptin treatment has vasculo-protective effects in lipodystrophic mice.

Proc. Natl. Acad. Sci. U.S.A. 119:e2110374119 (2022)
Publ. Version/Full Text Research data DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Lipodystrophy syndromes (LDs) are characterized by loss of adipose tissue, metabolic complications such as dyslipidemia, insulin resistance, and fatty liver disease, as well as accelerated atherosclerosis. As a result of adipose tissue deficiency, the systemic concentration of the adipokine leptin is reduced. A current promising therapeutic option for patients with LD is treatment with recombinant leptin (metreleptin), resulting in reduced risk of mortality. Here, we investigate the effects of leptin on endothelial to mesenchymal transition (EndMT), which impair the functional properties of endothelial cells and promotes atherogenesis in LD. Leptin treatment reduced inflammation and TGF-β2-induced expression of mesenchymal genes and prevented impairment of endothelial barrier function. Treatment of lipodystrophic- and atherosclerosis-prone animals (Ldlr-/-; aP2-nSrebp1c-Tg) with leptin reduced macrophage accumulation in atherosclerotic lesions, vascular plaque protrusion, and the number of endothelial cells with mesenchymal gene expression, confirming a reduction in EndMT in LD after leptin treatment. Treatment with leptin inhibited LD-mediated induction of the proatherosclerotic cytokine growth/differentiation factor 15 (GDF15). Inhibition of GDF15 reduced EndMT induction triggered by plasma from patients with LD. Our study reveals that in addition to the effects on adipose tissue function, leptin treatment exerts beneficial effects protecting endothelial function and identity in LD by reducing GDF15.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
12.779
0.000
5
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Atherosclerosis ; Endmt ; Gdf15 ; Leptin ; Lipodystrophy; To-mesenchymal Transition; Insulin-resistance; Adipose-tissue; Aortic-arch; Atherosclerotic Plaque; Diabetes-mellitus; Obesity; Atheromas; Risk; Endothelin-1
Language english
Publication Year 2022
HGF-reported in Year 2022
ISSN (print) / ISBN 0027-8424
e-ISSN 1091-6490
Journal Proceedings of the National Academy of Sciences of the United States of America
Quellenangaben Volume: 119, Issue: 40, Pages: , Article Number: e2110374119 Supplement: ,
Publisher National Academy of Sciences
Publishing Place 2101 Constitution Ave Nw, Washington, Dc 20418 Usa
Reviewing status Peer reviewed
Institute(s) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
POF-Topic(s) 30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-555000-001
G-506501-001
Grants German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
DOI 10.1073/pnas.2110374119
WOS ID 001009398200001
Scopus ID 85138648490
PubMed ID 36161905
Erfassungsdatum 2022-10-13
[➜Report correction]